AIFA — authorised 30 May 2020
- Marketing authorisation holder: Sanofi-Aventis groupe
- Status: approved
AIFA authorised Hu38Sb19 on 30 May 2020
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. AIFA authorised it on 30 May 2020.
Sanofi-Aventis groupe holds the Italian marketing authorisation.